<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03673618</url>
  </required_header>
  <id_info>
    <org_study_id>Phoenixchildrens-18-121</org_study_id>
    <nct_id>NCT03673618</nct_id>
  </id_info>
  <brief_title>Soluble Corn Fiber Supplementation for Asthma</brief_title>
  <official_title>Soluble Corn Fiber Supplementation for Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Phoenix Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northern Arizona University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Flinn Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Phoenix Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies of the importance of the human microbiome have demonstrated that microbial&#xD;
      metabolites of fermentation of our dietary products (e.g. dietary fiber) have a multitude of&#xD;
      health benefits. The investigators aim to determine whether supplementation of asthmatic&#xD;
      children with soluble corn fiber alongside standard of care reduces airway inflammation&#xD;
      driven by the gut microbial metabolites acetate, propionate, or butyrate (short chain fatty&#xD;
      acids).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Asthma is a complex inflammatory disease of the airways that is estimated to affect 300&#xD;
      million people worldwide. Incidence of asthma is steadily increasing in Western populations;&#xD;
      an additional 100 million asthma diagnoses are anticipated by the year 2025. Asthma is a&#xD;
      multifactorial disease affected by genetic and environmental factors. One major and&#xD;
      potentially modifiable environmental factor is the Western diet. The Western diet influences&#xD;
      the microbiome, which in turn, may influence inflammatory airway diseases via a gut&#xD;
      microbiome-airway connection. The investigators hypothesize that prebiotic dietary fiber&#xD;
      supplementation leads to increased circulating short chain fatty acid production and&#xD;
      improvement in asthma disease activity. The investigators will recruit 20 children, ages 6-17&#xD;
      years old, with asthma from the Severe Asthma Clinic or General Pulmonary Clinic at Phoenix&#xD;
      Children's Hospital. Participants will be randomly assigned (1:1) using a random number&#xD;
      generator to ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored&#xD;
      beverage or placebo (malodextrin in a similar fruit-flavored beverage) as previously&#xD;
      described. Participants will be asked to consume the prebiotic soluble corn fiber (or&#xD;
      placebo) for 4 weeks alongside their normal diet and normal asthma treatments. Blood will be&#xD;
      collected pre- and post-fiber intervention to measure baseline and post-intervention&#xD;
      circulating SCFAs. Stool samples and nasal wash will be collected for microbiome and immune&#xD;
      analysis pre- and post- fiber consumption. Nasal washes will be collected pre- and post-fiber&#xD;
      consumption to measure inflammatory patterns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">August 28, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>A study pharmacist will provide soluble corn fiber or a placebo (malodextrin) in identical packets to be dispensed in identical fruit-flavored beverage</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>Asthma Control Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Short Chain Fatty Acids</measure>
    <time_frame>Before treatment period and after treatment for 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in nasal wash Th2 gene expression</measure>
    <time_frame>Before treatment period and after treatment for 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha and beta diversity in participants' nasal microbiome</measure>
    <time_frame>Before treatment period and after treatment for 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alpha and beta diversity in participants' stool microbiome</measure>
    <time_frame>Before treatment period and after treatment for 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>PROMOTIR soluble corn fiber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will ingest PROMOTIR soluble corn fiber (85% fiber, 12 g/day) in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Malodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will ingest malodextrin in a fruit-flavored beverage for 4 weeks alongside their normal diet and normal asthma treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Soluble Corn Fiber</intervention_name>
    <description>Fiber or placebo</description>
    <arm_group_label>Malodextrin</arm_group_label>
    <arm_group_label>PROMOTIR soluble corn fiber</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of asthma&#xD;
&#xD;
          -  Fractional excretion of exhaled nitric oxide (FeNO) &gt; 50 ppb OR a history of&#xD;
             environmental allergies&#xD;
&#xD;
          -  No emergency department or hospital visits for asthma in the past 3 months&#xD;
&#xD;
          -  No systemic corticosteroids in the past 1 month&#xD;
&#xD;
          -  Ability to consume a liquid drink of SCF or placebo&#xD;
&#xD;
          -  Ability to return for a 4-6 week follow-up visit&#xD;
&#xD;
          -  No special or unique diet as determined by PI/CO-Is.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Bronchiectasis&#xD;
&#xD;
          -  Change in asthma medicines other than short acting bronchodilators planned over the&#xD;
             next 4-6 weeks.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Matthew A Rank, MD</last_name>
    <phone>480-301-4284</phone>
    <email>rank.matthew@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James Woodward, MD</last_name>
    <phone>602-933-5437</phone>
    <email>jwoodward@phoenixchildrens.com</email>
  </overall_contact_backup>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2018</study_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

